{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:19:38Z","timestamp":1791047978245,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cgh.2025.07.030","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:57:50Z","timestamp":1754438270000},"page":"525-534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Phase 2 Study of MORF-057, an Oral \u03b14\u03b27 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E.","family":"Sands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Kierkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brihad","family":"Abhyankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dooyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maloy","family":"Mangada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce N.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.07.030_bib1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.07.030_bib2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.mayocp.2019.01.018","article-title":"Ulcerative colitis","volume":"94","author":"Feuerstein","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 3","key":"10.1016\/j.cgh.2025.07.030_bib3","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.07.030_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000527452","article-title":"Significance of 5-aminosalicylic acid intolerance in the clinical management of ulcerative colitis","volume":"104","author":"Mikami","year":"2023","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2025.07.030_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221102283","article-title":"Targeting IL12\/23 in ulcerative colitis: update on the role of ustekinumab","volume":"15","author":"Pugliese","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.030_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/med.21601","article-title":"The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti-integrin therapies","volume":"40","author":"Dotan","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.cgh.2025.07.030_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1083\/jcb.201110023","article-title":"Structural specializations of alpha(4)beta(7), an integrin that mediates rolling adhesion","volume":"196","author":"Yu","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1016\/j.cgh.2025.07.030_bib8","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cgh.2025.07.030_bib9","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14 \u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.07.030_bib10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.07.030_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.07.030_bib14","series-title":"Morphic Therapeutic","year":"2023"},{"key":"10.1016\/j.cgh.2025.07.030_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/gutjnl-2015-310393","article-title":"Development and validation of a histological index for UC","volume":"66","author":"Mosli","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.07.030_bib16","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1038\/ctg.2012.23","article-title":"HLA-DR(hi) and CCR9 define a pro-inflammatory monocyte subset in IBD","volume":"3","author":"Linton","year":"2012","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.030_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","article-title":"Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY)","volume":"161","author":"Peyrin-Biroulet","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.07.030_bib18","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/MIB.0b013e318280e75f","article-title":"Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis","volume":"19","author":"Lemmens","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.07.030_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.14309\/ajg.0000000000000437","article-title":"Histological remission in ulcerative colitis: under the microscope is the cure","volume":"115","author":"Chateau","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.030_bib20","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"159","author":"Yoon","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.07.030_bib21","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/21645515.2019.1591139","article-title":"A product review of vedolizumab in inflammatory bowel disease","volume":"15","author":"Battat","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cgh.2025.07.030_bib22","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.3390\/ijms24065820","article-title":"Differences in whole-blood transcriptional profiles in inflammatory bowel disease patients responding to vedolizumab compared with non-responders","volume":"24","author":"Haglund","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cgh.2025.07.030_bib23","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/MIB.0000000000000059","article-title":"CCL25\/CCR9 interactions are not essential for colitis development but are required for innate immune cell protection from chronic experimental murine colitis","volume":"20","author":"Wurbel","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.07.030_bib24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525006482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525006482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:43:36Z","timestamp":1779219816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525006482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1542356525006482"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.07.030","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Study of MORF-057, an Oral \u03b14\u03b27 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}